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Edited by Veli-Pekka LehtoAbstract Survival of tissue transplants generated in vitro is
strongly limited by the slow process of graft vascularization
in vivo. A method to enhance graft vascularization is to establish
a primitive vascular plexus within the graft prior to transplanta-
tion. Endothelial cells (EC) cultured as multicellular spheroids
within a collagen matrix form sprouts resembling angiogenesis
in vitro. However, osteoblasts integrated into the graft suppress
EC sprouting. This inhibition depends on direct cell–cell-interac-
tions and is characteristic of mature ECs isolated from preexist-
ing vessels. In contrast, sprouting of human blood endothelial
progenitor cells is not inhibited by osteoblasts, making these cells
suitable for tissue engineering of pre-vascularized bone grafts.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Endothelial progenitor cells; Osteoblasts; Tissue
engineering; Sprouting; Angiogenesis; Spheroid culture1. Introduction
After embryonic development the regenerative capacity of
human tissues is generally limited. To repair congenital defects
or to replace tissues destroyed by disease or injury, various
techniques of tissue engineering are being developed to provide
graft material for reconstructive surgery. One of the main
problems for the successful application of ex vivo generated
human tissue for transplantation purposes is the slow ingrowth
of blood vessels, leading to cell loss through hypoxic cell death
during the early post-implantational stage [1]. Lack of oxygen
and nutrients, especially in the central regions of transplants,
limit the three-dimensional size of tissue-engineered constructs
dramatically [2]. The best results have been obtained with
replacements that are thin and stretched out, such as skin or
inner vascular layers [3,4]. The ingrowth of blood vessels into
hypoxic tissues is accelerated by addition of proangiogenic
growth factors [2,5]. Another promising approach is the gener-
ation of composite grafts, which contain not only speciﬁc cell
types characteristic for the respective tissue, but also endothe-
lial cells (ECs). Composites with an integrated primitive vascu-
lar plexus might be especially beneﬁcial, if host vessels connect
to the preformed vascular system to rapidly establish a func-
tional circulation within the construct.*Corresponding author. Fax: +1 617 730 0233.
E-mail address: Peter.kurschat@childrens.harvard.edu (P. Kurschat).
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doi:10.1016/j.febslet.2005.09.005As reconstructive surgery often involves the replacement of
bone tissue, the in vitro generation of osteogenic matrices
has become one of the prime objectives of tissue engineering
research. In order to design vascularized bone substitutes,
the sprouting of EC spheroids combined with osteoblast cul-
tures has been used to generate a collagen matrix which acco-
modates both bone stromal cells as well as EC tubes [6].
Unfortunately, the presence of osteoblasts in co-spheroids sup-
pressed endothelial sprouting by a so far unidentiﬁed mecha-
nism [6].
Another challenge for vascularizing three-dimensional grafts
successfully is to ﬁnd an abundant source of autologuous ECs.
The isolation of these cells from skin biopsies yields only lim-
ited numbers, and the expansion in vitro is limited by cell cycle
senescence after a few passages [7]. Endothelial progenitor cells
(EPCs) have been suggested as an EC source [8,9]. EPCs can be
isolated from bone marrow as well as from the peripheral
blood of both children and adults [10]. The proliferative
capacities of these cells are far higher than of mature ECs.
EPCs have already been proven suitable for tissue engineering
applications [9].
In the present study, we demonstrate that osteoblasts inte-
grated into the collagen matrix as suspended single cells inhibit
EC spheroid sprouting. This inhibition is dependent on direct
cell–cell contacts. In order to generate transplantable compos-
ite grafts with stromal cells beneﬁtting from preformed capil-
laries, EPCs were analyzed. In contrast to the results
obtained with mature ECs, the sprouting of EPC spheroids
was not inhibited by the presence of osteoblasts. We conclude
that EPCs provide a more promising source for the generation
of vascularized tissue-engineered bone grafts than other ECs.2. Materials and methods
2.1. Monolayer and spheroid cell culture
Human umbilical vein ECs (HUVECs) were obtained from Camb-
rex (Wakersville, MD) and used from passage 2–5. Cells were cultured
as monolayers at 37 C, 5% CO2 in a humidiﬁed atmosphere in EC
growth medium EGM-2 (Cambrex), containing 10% fetal bovine ser-
um (FBS) and glutamine, penicillin and streptomycin in standard con-
centrations (1% GPS, Gibco, Invitrogen, Carlsbad, CA). Primary
human osteoblasts were obtained from Cambrex and grown as mono-
layers in Medium 199 (Cambrex), supplemented with 10% FBS and 1%
GPS. For the preparation of osteoblast conditioned media, osteoblasts
were seeded into collagen gels (see below), and 48 h later the gel super-
natant was collected and centrifuged to remove cells or cell debris. Theblished by Elsevier B.V. All rights reserved.
A. Stahl et al. / FEBS Letters 579 (2005) 5338–5342 5339isolation and cultivation of EPCs is described below. The preparation
of EC spheroids was performed as described by [11]. Brieﬂy, cells were
harvested from subconﬂuent monolayer cultures by trypsinization and
suspended in EGM-2 containing 10% FBS and 0.25% (w/v) carboxy-
methylcellulose (Sigma, St. Louis, MO). Five hundred cells per well
were seeded into non-adherent round-bottom 96-well plates to assem-
ble into a single spheroid within 24 h at 37 C, 5% CO2.2.2. Endothelial cell sprouting assay in collagen gels
Sprouting of EC spheroids into a matrix of type I collagen as an
assay of in vitro angiogenesis was described before by [12]. For each
collagen gel, 30 spheroids were seeded into 0.7 ml collagen solution in
non-adherent 24-well plates, with a ﬁnal concentration of rat type I
collagen (isolated from tail tendons, BD Bioscience, Bedford, MA)
of 1.5 mg/ml. For gels containing human osteoblasts, 15000 cells in
single cell suspension were added prior to polymerization. Freshly
prepared gels were transferred rapidly into a humidiﬁed incubator
(37 C, 5% CO2) and after polymerization, 0.25 ml EGM-2 with
10% FBS was added per well. Vascular endothelial growth factor
(human recombinant VEGF165, R&D Systems, Minneapolis, MN)
and basic ﬁbroblast growth factor (human recombinant bFGF, BD
Bioscience) were added as indicated, in a ﬁnal concentration of
25 ng/ml. After 36 h, gels were photographed and spheroid sprouting
was assessed quantitatively. As described before [6], the cumulative
sprout length of 10 randomly selected spheroids was measured to cal-
culate mean sprout length and S.D. for each group. Brieﬂy, the
length of all capillary-like sprouts originating from the cental plain
of an individual spheroid were added to one value. Results for the
diﬀerent experimental groups were expressed as means ± S.D., and
the diﬀerences between groups were analyzed by unpaired Student t
test. A P-value < 0.05 was considered statistically signiﬁcant (), a
value <0.01 as highly signiﬁcant ().
2.3. Cell culture in transwell chambers
To assess the inﬂuence of direct cell–cell contacts, coculture assays of
EC spheroids and osteoblasts were performed in transwell chambers
(Costar, Fisher, Morris Plains, NJ). EC spheroids embedded in colla-
gen gels (30 spheroids per 0.7 ml gel, see above) were seeded into the
lower compartment of 24-well transwell chamber plates. Human oste-
oblasts (25000) were seeded onto the semipermeable membrane (pore
size 0.4 lm) of the upper compartment. After 36 h of incubation
(37 C, 5% CO2), the spheroids were photographed and analyzed for
sprouting activity.
2.4. Isolation of human EPCs
Endothelial progenitor cells from human umbilical cord blood were
isolated and characterized as described before [9]. Brieﬂy, mononuclear
cells (MNCs) were prepared from human umbilical cord blood (pro-
vided by the Brighams and Womens Hospital Boston in accordance
with an Institutional Review Board-approved protocol) by Ficoll Hyp-
aque (Amersham Pharmacia, Uppsala, Sweden) density gradient cen-
trifugation. Cells positive for both CD34 and CD133 were isolated
from the MNCs by two consecutive rounds of magnetic bead puriﬁca-
tion. First, CD34-positive cells were isolated with anti-CD34-conju-
gated superparamagnetic beads (Miltenyi Biotec, Auburn, CA). The
CD34+ population was further puriﬁed with anti-CD133/1 conjugated
microbeads, resulting in a preparation of CD34+/CD133+ cells. By
indirect immunoﬂuorescence using a second anti-CD133 antibody it
was shown that every individual cell stained positive. The amount of
60 ml cord blood typically provided 1–2 · 104 double positive cells.
Puriﬁed EPCs were further propagated as monolayers on tissue culture
dishes coated with 1% gelatin in EGM-2 medium containing 20% FBS
at 37 C, 5% CO2.
2.5. Fluorescent labelling and confocal microscopy
Cell surface labelling of ECs and osteoblasts was performed with
green and red ﬂuorescent dyes PKH 26 and PKH 67, respectively, ob-
tained from Sigma. Cells from monolayer cultures were harvested by
trypsinization and the staining procedure was performed according
to manufacturers instructions without modiﬁcation. Immediately after
the labelling, cells were used to generate spheroids (ECs) or seeded into
collagen gels (osteoblasts). Gels were photographed after 36 h with a
Leica DMIRE2 confocal laser microscope.3. Results
3.1. Osteoblasts suppress EC spheroid sprouting in collagen gels
Spheroids generated from HUVECs with a deﬁned cell
number of 500 cells per spheroid were embedded into type
I collagen gels and incubated for 36 h in the absence or pres-
ence of VEGF165 and bFGF (25 ng/ml each). There was al-
most complete absence of spheroid sprouting in groups
without angiogenic stimulation by VEGF165 and bFGF
(Fig. 1A). On the other hand, when both of the angiogenic
factors were added (Fig. 1B), the HUVEC spheroids extended
tube-like sprouts into the surrounding collagen matrix, con-
sistent with previous reports [6,12]. When osteoblasts were
incorporated into the collagen matrix in close proximity to
HUVEC spheroids (Fig. 1C), sprouting was inhibited almost
completely, despite the addition of VEGF165 and bFGF.
Measurement of the cumulative sprout length per spheroid
revealed that the baseline sprouting without angiogenic stim-
ulation was 160 lm, ±50 lm per spheroid. Addition of VEGF
and bFGF increased spheroid sprout length to 930 lm,
±280 lm. When osteoblasts were present within the gel, the
sprout length decreased signiﬁcantly to 110 lm, ±35 lm, de-
spite continuous angiogenic stimulation.
3.2. Inhibition of EC sprouting by osteoblasts is dependent on
cell–cell contacts
Next we investigated whether the inhibitory eﬀect of oste-
oblasts on EC spheroid sprouting is mediated by secreted,
soluble factors, or whether this eﬀect depends on direct
cell–cell-interactions (Fig. 2). The ﬁrst three lanes show
baseline (lane 1), growth factor-induced (lane 2) and osteo-
blast-inhibited (lane 3) sprouting, as demonstrated above.
Compared to the growth factor-induced sprouting, this inhi-
bition was highly signiﬁcant (P-value < 0.01). The addition
of osteoblast conditioned medium to HUVEC spheroids in
collagen gels did not inhibit HUVEC spheroid sprouting
(lane 4). Conditioned medium from gels containing no cells
was used as a control and showed no eﬀect on EC sprouting
(lane 5). Transwell chambers were used to coculture both
cell types without direct cell–cell contacts, but sharing the
same media. Again, sprouting of HUVEC spheroids was
not inhibited by osteoblasts seeded into the upper transwell
chamber (lane 6). These results rule out the possibility that
HUVECs induce osteoblasts to secret soluble anti-angiogenic
factors, which are responsible for the observed inhibition in
direct coculture. Therefore, the inhibitory eﬀects of osteo-
blasts on EC sprouting depend on direct cell–cell-interac-
tions and are not mediated by soluble factors.
3.3. Sprouting of EPC spheroids is not inhibited by osteoblasts
We investigated whether spheroid sprouting of human
EPCs isolated from cord blood was inhibited by osteoblasts,
similar to inhibition of HUVEC sprouting. Baseline sprout-
ing of EPC spheroids without further angiogenic stimulation
was higher than observed for HUVEC spheroids (Fig. 3A).
Addition of VEGF165 and bFGF increased sprouting activ-
ity further (Fig. 3B). When osteoblasts were seeded into
the gels, EPC spheroids continued to sprout into the sur-
rounding collagen matrix (Fig. 3C). Quantiﬁcation of the
cumulative sprout length (Fig. 3D) revealed that the EPC
baseline sprouting of 380 lm, ±160 lm, was increased by
EC growth factors to 1400 lm, ±350 lm. The presence of
Fig. 1. Sprouting of HUVEC spheroids in collagen gels. Spheroids consisting of 500 cells each were embedded into type I collagen gels. After 36 h,
spheroid sprouting was analyzed. (A) Low baseline sprouting was observed. (B) In the presence of VEGF165 and bFGF both sprout number and
sprout length increased signiﬁcantly. (C) When single osteoblasts were seeded into the collagen matrix, HUVEC sprouting was inhibited almost
completely.
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sprouting and reduced this value to 1280 lm, ±320 lm,
which was not statistically signiﬁcant.
For a better visualization of the direct interaction between
the two cell types, osteoblasts were labelled with a green ﬂuo-
rescent surface dye, whereas HUVEC or EPC spheroids were
labelled red. HUVEC spheroid sprouting in collagen gels con-
taining osteoblasts was absent, despite angiogenic stimulationFig. 2. Inhibition of HUVEC spheroid sprouting by osteoblasts
depends on direct cell–cell-contacts. Lanes 1 and 2 show baseline and
growth factor-induced cumulative sprout length of HUVEC spheroids
in collagen gels. Lane 3 shows the highly signiﬁcant () inhibition of
growth factor-induced sprouting after addition of osteoblasts. Condi-
tioned medium (CM) of osteoblasts grown in collagen gels was unable
to induce a similar inhibition (lane 4). Conditioned medium from
empty collagen gels (CG) served as a negative control to exclude eﬀects
from the collagen gel itself (lane 5). No inhibition of sprouting was
observed when HUVEC spheroids and osteoblasts were cocultured in
transwell chambers (TW), with direct cell–cell-contacts between the
two cell types prevented by a porous membrane inset (lane 6).(Fig. 4A), whereas EPC spheroids extended sprouts into the
matrix, although osteoblasts were in close contact to the
EPC spheroid (Fig. 4B).4. Discussion
The successful use of tissue-engineered transplants is ham-
pered by the need for vascularization. A solution would be
to provide a preformed primitive vascular plexus within the
transplant which could be used by preexisting host vessels to
form anastomoses, thereby accelerating vessel ingrowth. In
animal models, it has been demonstrated that a preformed vas-
cular plexus in collagen gels can be utilized and perfused [13].
Because of immunological reasons and the risk of infection,
autologous ECs are considered the best material for this pur-
pose. Unfortunately, mature ECs isolated from for example
skin tissue have limited proliferative capacities and become
senescent after a maximum of 30 cell divisions, which makes
large scale skin biopsies necessary to yield the required cell
number [7]. However, EPCs isolated from peripheral blood
or bone marrow have been shown to be able to undergo more
than 1000 divisions, which means that even the comparatively
low numbers of EPCs in adults should be suﬃcient to provide
the required amount of cells [10]. Therefore, the use of EPCs
for tissue engineering has been suggested [14]. EPCs are usu-
ally deﬁned as CD133+/VEGFR-2+ cells, isolated from a pop-
ulation of CD34+ cells [10,15,16]. When cultured in vitro, these
cells loose the stem cell marker CD133, but they continue to
express EC markers such as VEGFR-2, VE-cadherin, CD31,
vWF and E-selectin, thus maintaining their endothelial iden-
tity [9].
The tissue engineering of bone substitutes provides several
speciﬁc challenges [17]. Wenger and et al. [6] attempted to ex-
ploit the EC spheroid culture system to generate constructs for
Fig. 3. EPC spheroid sprouting is not inhibited by osteoblasts. As in Fig. 1, EPC spheroids were cultured in collagen gels. (A) Baseline sprouting was
more pronounced, compared to HUVEC spheroids. (B) The addition of growth factors further increased sprout number and length. (C) The presence
of osteoblasts in the gel did not inhibit EPC sprouting. (D) Quantiﬁcation of cumulative sprout length demonstrates the lack of EPC sprout
inhibition in the presence of osteoblasts.
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of ECs cultured as multicellular spheroids to form lumenized
structures resembling sprouting angiogenesis [12]. Further-
more, spheroidal ECs are protected from apoptosis and show
increased diﬀerentiation, as opposed to ECs in monolayer cul-
tures, which tend to lose their EC markers over prolonged
times of culture [11]. Unfortunately, in these studies the inclu-
sion of osteoblasts into the EC spheroids caused a suppression
of EC sprouting [6]. We observed a similar inhibition even
when osteoblasts were not integrated directly into the HUVEC
spheroids, but rather suspended into the surrounding collagen
matrix. Sprouting of spheroids prepared from human micro-
vascular endothelial cells (HMVECs) was also inhibited by
osteoblasts (unpublished data). Previous studies have shown
that EC–osteoblast interactions lead to changes of gene expres-
sion in a contact-dependent manner, whereas conditioned
media from either cell type had almost no inﬂuence on the geneFig. 4. Colocalization of EC spheroids and osteoblasts in collagen gels. To
osteoblasts were labelled with a green ﬂuorescent cell surface stain, whereas H
was inhibited by osteoblasts, which are located in immediate proximity to the
by the presence of osteoblasts, despite direct cell contact between both cell texpression proﬁle of the other cell type [18]. For the interaction
of HUVECs with human osteoprogenitor cells it has been
demonstrated that connexin43 and the formation of gap junc-
tions are crucial for the interaction between these two cell types
[19]. This result is consistent with our transwell experiments
which indicate that inhibition of EC sprouting by osteoblasts
depends on direct cell–cell contacts and is not mediated by sol-
uble factors, although at this point we cannot completely ex-
clude that the inability of conditioned media to suppress EC
sprouting might be the consequence of short half life or limited
mobility of secreted factors. Future work is needed to identify
the receptors or adhesion molecules responsible for the inhib-
itory eﬀect of osteoblasts on EC sprouting.
Similar observations of EC quiescence were found when EC
spheroids were grown in direct contact to smooth muscle cells
[20]. Furthermore, both pericytes and smooth muscle cells
have been shown to inhibit EC proliferation and migration.demonstrate the close proximity of both cell types in collagen gels,
UVECs or EPCs were labelled red. (A) HUVEC cell spheroid sprouting
spheroid (arrows). (B) Sprouting of EPC spheroids was not suppressed
ypes (arrows).
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cytes stabilizes newly formed vessels but also marks the end
of active sprouting angiogenesis [21]. The observation that
osteoblasts inhibit EC sprouting indicates that stromal cells
other than pericytes or smooth muscle cells are capable of
inhibiting sprouting angiogenesis. Sprouts formed by EC
spheroids consist of migrated ECs [12]. Therefore, the impair-
ment of migratory processes might be responsible for the sup-
pression of EC spheroid sprouting.
In contrast to the inhibition of mature EC sprouting by oste-
oblasts, the sprouting of EPCs is not abolished by the presence
of osteoblasts. The reasons for resistance to osteoblast inhibi-
tion remain to be investigated. It should be noted that not only
mature human osteoblasts but also bone marrow-derived
osteoprogenitor cells have been suggested for tissue engineer-
ing purposes [22]. These cells might have similar advantages
like EPCs and have been shown to secrete VEGF. Preosteo-
blastic MC3T3-E1 cultured in 3D systems were able to increase
in vitro angiogenesis, which indicates that osteoprogenitors
might not display the same inhibitory eﬀect on EC sprouting
as observed by mature osteoblasts [23]. However, the conse-
quence from our study is that in addition to the advantages
over mature ECs in terms of cell isolation and proliferative
capacity, EPCs appear to be the superior material for the gen-
eration of pre-vascularized tissue-engineered bone grafts.
Seeded into a collagen matrix, EPCs sprout very well and seem
to be less dependent on angiogenic stimulation, since the base-
line sprouting in the absence of VEGF165 and bFGF is higher
than in HUVEC or HMVEC spheroids. EPCs isolated from
peripheral blood might therefore prove to be a valuable and
powerful tool for ex vivo generated bone replacements in the
future.
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